Sponsor

Peking University Shenzhen Hospital

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Peking University Shenzhen Hospital appears in 15 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials15
Recruiting shown4
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

15 shown
Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After LorlatinibNCT07374614 · lead sponsor · 2026-01-31
RECRUITING
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast CancerNCT07095023 · collaborator · 2025-08-15
RECRUITING
AI-Assisted System for Accurate Diagnosis and Prognosis of Breast Phyllodes TumorsNCT06286267 · collaborator · 2023-03-01
RECRUITING
Adjuvant Chemotherapy for High Malignant Prostate CancerNCT06864533 · collaborator · 2019-09-01
RECRUITING
Breast Phyllodes Tumors: Based on 20-year Real-world Data From ChinaNCT07636096 · collaborator · 2026-05-01
COMPLETED
Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLCNCT07377916 · collaborator · 2026-02-15
NOT_YET_RECRUITING
Trastuzumab Plus Taxane Neoadjuvant Therapy for HER2-Positive Breast Ductal Carcinoma In Situ (DCIS) : A Phase II StudyNCT06843681 · collaborator · 2025-03-01
ENROLLING_BY_INVITATION
A Clinical Study on Exercise Guided by CPET to Reduce the Risk of Metabolic Cardiovascular Diseases(C-MET Trial)NCT06528639 · collaborator · 2024-05-21
UNKNOWN
Normal Chinese Lifespan Brain Charts Initiative (NCLBCI)NCT06643858 · collaborator · 2023-12-01
ENROLLING_BY_INVITATION
The Characteristics, Treatment Patterns and Prognosis of Chinese Male Breast Cancer: A Real-world StudyNCT06220630 · collaborator · 2021-08-01
UNKNOWN
Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)NCT04923802 · collaborator · 2021-06-24
TERMINATED
A Study of Efficacy and Safety of Idebenone Vs. Placebo in Prodromal Parkinson DiseaseNCT04152655 · collaborator · 2020-01-01
WITHDRAWN
Study of Efficacy, Weight Control, and Safety in Newly-diagnosed Type 2 Diabetes With Different Antidiabetic TherapyNCT03700801 · collaborator · 2018-10-01
COMPLETED
Circulating Tumor DNA in Surgical Lung Cancer PatientsNCT03081741 · collaborator · 2017-05-03
UNKNOWN
Effects of Different Early Intensive Therapies on Long-term β-cell FunctionNCT01471808 · collaborator · 2011-10-01
COMPLETED

Drugs studied in this sponsor's trials

3 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Peking University Shenzhen Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
docetaxel1
idebenone1
placebo Oral Tablet1

Sponsor roles

collaborator14
lead sponsor1
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.